DK3619237T3 - Antistoffer mod karcinoembryonalt antigen til cancerterapi og -diagnosticering - Google Patents

Antistoffer mod karcinoembryonalt antigen til cancerterapi og -diagnosticering Download PDF

Info

Publication number
DK3619237T3
DK3619237T3 DK18722497.7T DK18722497T DK3619237T3 DK 3619237 T3 DK3619237 T3 DK 3619237T3 DK 18722497 T DK18722497 T DK 18722497T DK 3619237 T3 DK3619237 T3 DK 3619237T3
Authority
DK
Denmark
Prior art keywords
diagnosis
antibodies against
cancer therapy
carcinoembryonal antigen
carcinoembryonal
Prior art date
Application number
DK18722497.7T
Other languages
English (en)
Inventor
Armelle Cuvillier
Gaël Champier
Original Assignee
B Cell Design
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B Cell Design filed Critical B Cell Design
Application granted granted Critical
Publication of DK3619237T3 publication Critical patent/DK3619237T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK18722497.7T 2017-05-04 2018-05-03 Antistoffer mod karcinoembryonalt antigen til cancerterapi og -diagnosticering DK3619237T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305498.2A EP3398967A1 (en) 2017-05-04 2017-05-04 Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis
PCT/EP2018/061385 WO2018202794A1 (en) 2017-05-04 2018-05-03 Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis

Publications (1)

Publication Number Publication Date
DK3619237T3 true DK3619237T3 (da) 2024-04-08

Family

ID=58707444

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18722497.7T DK3619237T3 (da) 2017-05-04 2018-05-03 Antistoffer mod karcinoembryonalt antigen til cancerterapi og -diagnosticering

Country Status (8)

Country Link
US (1) US11427646B2 (da)
EP (2) EP3398967A1 (da)
AU (1) AU2018262648A1 (da)
CA (1) CA3062233A1 (da)
DK (1) DK3619237T3 (da)
FI (1) FI3619237T3 (da)
PT (1) PT3619237T (da)
WO (1) WO2018202794A1 (da)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers

Also Published As

Publication number Publication date
EP3619237A1 (en) 2020-03-11
FI3619237T3 (fi) 2024-04-19
WO2018202794A1 (en) 2018-11-08
AU2018262648A1 (en) 2019-11-07
EP3398967A1 (en) 2018-11-07
US20200055952A1 (en) 2020-02-20
CA3062233A1 (en) 2018-11-08
EP3619237B1 (en) 2024-01-17
PT3619237T (pt) 2024-03-05
US11427646B2 (en) 2022-08-30

Similar Documents

Publication Publication Date Title
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
HK1257730A1 (zh) 抗despr單克隆抗體用於癌症和中風的靶向療法及成像
DK3458102T3 (da) Anti-cmet-antistoflægemiddelkonjugater og fremgangsmåder til anvendelse deraf
DK3459597T3 (da) Enkeltdomæne-antistof mod ctla4 og deraf afledt protein
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
DK3294770T3 (da) Terapeutiske og diagnostiske fremgangsmåder til cancer
DK3271389T3 (da) Neutraliserende antistoffer mod gp120 og anvendelse deraf
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
DK3309174T3 (da) ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
DK3508502T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK3142689T3 (da) Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3
DK3166973T3 (da) Immunstimulerende monoklonale antistoffer mod human interleukin-2
DK3512882T3 (da) Anti-c-met-antistoffer og antistoflægemiddelkonjugater deraf til effektiv tumorinhibering
EP3502142A4 (en) BISPECIFIC ANTIBODY AND ANTIBODY CONJUGATE FOR TUMOR THERAPY AND USE THEREOF
HUE052528T2 (hu) Anti szklerosztin antitest, antigénkötõ fragmens és annak orvosi használata
DK3154583T3 (da) Humane monoklonale antistoffer mod gangliosid gd2
DK3317300T3 (da) Bispecifikke antistoffer til anvendelse i kræftimmunterapi
HK1243439A1 (zh) Pcsk9抗體、其抗原結合片段及其醫藥用途
HK1243434A1 (zh) Igf-1r抗體及其診斷癌症的用途
DK3630177T3 (da) Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling
DK3619237T3 (da) Antistoffer mod karcinoembryonalt antigen til cancerterapi og -diagnosticering
HK1248730A1 (zh) Igf-1r抗體及其用於癌症診斷的用途
DK3344287T3 (da) Anti-survivin-antistoffer til cancerterapi
EA201692560A1 (ru) Моноклональные антитела против эпитопа her2 и способы их применения